Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22229
Title: RET-rearranged non-small-cell lung cancer and therapeutic implications.
Austin Authors: Loh, Zoe ;Mitchell, Paul L R ;John, Thomas ;Arulananda, Surein
Affiliation: Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Issue Date: Dec-2019
Publication information: Internal Medicine Journal 2019; 49(12): 1541-1545
Abstract: First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22229
DOI: 10.1111/imj.14654
ORCID: 0000-0002-9215-1441
0000-0002-5636-6381
PubMed URL: 31808254
Type: Journal Article
Subjects: RET rearrangement
genomic profiling
non-small-cell lung cancer
tyrosine kinase inhibitor
vandetanib
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Mar 8, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.